LICENSE AGREEMENT WITH 3D MEDICINES AND GLENMARK FOR KN035License Agreement • August 15th, 2018
Contract Type FiledAugust 15th, 2018This announcement is made by Alphamab Oncology (the “Company”, together with its subsidiaries, the “Group”) on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business advancement of the Group.